Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

<< Previous

Bullboard Posts

Next >>

Post by Jesus4Prezon Feb 08, 2021 7:14pm

257 Views

Post# 32508143

Apabetalone Commercialization

If Apabetalone gets the nod for mass production and commercialization based on covid emergency clearance, and is so safe, why not ask the FDA to allow for data collection on a broader basis from all participants and Voila, you have a Phase 4 Trial.

<< Previous

Bullboard Posts

Next >>

Dynamic Funds Launches new ETF series on the TSX